Read our Recent Headlines

October 12 Biotech Update

Another start to the week and another week without the M&A that many think is needed to move the sector higher. I worry a little about that argument as one.

October 9 Biotech Update

I would say after yesterday that the sector looks a little better but I think more to the point it seems that volatility is the best word that describes the.

October 7 Biotech Update

So I think the sector told us what direction it wanted to move. We are getting to dangerous territory for another large leg downward. It does not help in the.

October 5 Biotech Update

Today is going to be a nice tell for the sector. We essentially have a positive market backdrop but more importantly competing headlines. There is the continued pricing discussion highlighted.

STARTRK-1: Lost In Space [RXDX]

This is a brief analysis of recent entrectinib data presented by Ignyta. Entrectinib is a multi-kinase inhibitor with potent activity against TrkA/B/C, ROS1, and ALK. It was licensed from Nerviano.

Sarepta Patent Issue – Ask The USPTO Reg Attorney

  This week BioMarin (BMRN) announced it won the first  DMD patent battle against Sarepta (SRPT) in a press release stating, “BioMarin Receives Favorable Ruling in the Use of Exon.

October 2 Biotech Update

Just when it seemed like the market could have been getting its footing we have the weak jobs report and we are back to a macro driven sell off. I.


Quick Facts














Chimera Research Group provides completely independent and actionable investment and trading ideas backed by comprehensive fundamental research and analysis for listed companies in the biotech and pharmaceutical sectors. Our coverage focuses on early stage companies with impending FDA decisions or clinical trial results but also includes mid-to-large cap bio-pharma companies where there exists specific catalysts. Our Trade Ideas are designed to maximize the risk reward profile. Our Research Reports outline the top up-and-coming catalysts that represent the best opportunities for traders and investors.

The biopharmaceutical sector offers significant opportunities to generate big returns yet can be risky and difficult to navigate. Subscribe to Chimera Research Group and proceed with confidence.

Get Started!